missouri medicaid glp 1 GLP-1 coverage for obesity treatment in 13 US states' programs Does this mean Zepbound is

Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors

According to the company, the compound demonstrated approximately 15% weight loss in preclinical testing compared with roughly 9% observed with liraglutide, while food intake reductions approached 39% versus approximately 20% for the comparator

Here is the honest evidence status up front: the individual compounds have real human data Tesamorelin is an FDA-approved prescription drug (EGRIFTA) for HIV-associated lipodystrophy, and Ipamorelin has been characterized in human GH-release studies but the fixed Tesamorelin + Ipamorelin blend as sold for research has no completed human randomized controlled trial of its own

There is no mention of patient satisfaction with their appearance posttreatment in any of the trials